Regeneron Pharmaceuticals Plummets to 157th in Trading Volume Ranking Amid FDA Decision Anticipation

On March 27, 2025, Regeneron Pharmaceuticals (REGN) experienced a significant decline, with a trading volume of $516 million, marking a 35.37% decrease from the previous day. This placed Regeneron at the 157th position in terms of trading volume for the day, with the stock price dropping by 0.67%.

Regeneron Pharmaceuticals is currently awaiting FDA decisions on its drug EYLEA HD, with a scheduled review and decision date under the Prescription Drug User Fee Act (PDUFA). The FDA has accepted the New Drug Application (NDA) for EYLEA HD, and the target date for the PDUFA decision is set for 10 months from the acceptance date of March 27, 2024.

The PDUFA date is a critical milestone for pharmaceutical companies, as it represents the deadline by which the FDA must complete its review of a drug application. This date is mandated by the Prescription Drug User Fee Act, which ensures timely reviews and approvals of new drugs. Regeneron's stock performance is closely tied to the outcomes of these regulatory decisions, as positive news can drive investor confidence and stock prices upward, while delays or negative outcomes can lead to declines.